T-lymphoblastic Lymphoma Clinical Trial
Official title:
A Phase Ib/II Clinical Trial of Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
The patients diagnosed with relapsed/refractory or advanced NK/T-cell Lymphoma (r/r NKTCL) were selected as the research objects. To explore effective and safe treatment for advanced or r/r NKTCL, the combination of PI3K-δ inhibitor Linperlisib with PD-1 blockade Camrelizumab and anti-metabolic agent Pegaspargase was applied for the treatment.
This is a prospective, single-arm, single-center Ib/II clinical trial that included an initial safety run-in phase with safety monitoring before the main enrollment (expansion phase).The aim of phase Ib is to evaluate the recommended phase 2 dose and dose-limiting toxicity (DLT), and the aim of phase II study is to evaluate, for the first time, the safety and efficacy of the treatment of Linperlisib combined with PD-1 blockade Camrelizumab and Pegaspargase in patients diagnosed with advanced or r/r ENKTL, respectively. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT05170828 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT04620655 -
RD13-01 for Patients With r/r CD7+ T-ALL/T-LBL
|
N/A | |
| Recruiting |
NCT04582487 -
Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL
|
N/A | |
| Suspended |
NCT04828174 -
Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies
|
Phase 1 | |
| Not yet recruiting |
NCT05068401 -
Cryopreserved MMUD BM With PTCy for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03558412 -
A Clinical Trial of Decitabine in Relapsed or Refractory T-lymphoblastic Lymphoma
|
Phase 4 | |
| Recruiting |
NCT05576532 -
Venetoclax Plus IM2 Regimen for Relapsed and Refractory T Lymphoblastic Lymphoma/Leukemia
|
Phase 2 | |
| Withdrawn |
NCT04860817 -
A Study of Anti-CD7 CAR-T Cells in Pediatric and Young Adult Patients With Relapse and Refractory T-ALL/ T-LBL
|
Early Phase 1 | |
| Recruiting |
NCT04004637 -
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT06136364 -
CD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
|
Phase 1 |